Pathogenesis of Impaired Cellular Immune Function in CLL

  • Patrick B. Johnston
  • Neil E. Kay
Chapter
Part of the Contemporary Hematology book series (CH)

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is defined as a monoclonal B-cell malignancy with a characteristic cell surface phenotype including expression of both CD19 and CD5 antigens (see Chapter 7). The clinical events characterizing the patients who eventually progress are most often linked to an accumulation of clonal CD5+ leukemic cells, particularly in the bone marrow, lymph nodes, and spleen. Although the hallmark of the leukemic CLL B-cell is its resistance to apoptosis, there is no significant insight into the exact biological reasons for that seminal biological event. It is probably true that critical genetic events are primary and lead to the B-cell resistance to apoptosis. However, we would hypothesize that the role of the microenvironment, including tissue-specific stroma, cytokine levels, vascular supply, and the host immune system, contribute to the augmentation and/or stabilize CLL B-cell apoptotic resistance. Thus, we have been interested in the study of both the qualitative and quantitative nature of the immune system in B-CLL.

Keywords

Chronic Lymphocytic Leukaemia Soluble CD23 Large Granular Lymphocyte Bone Marrow Plasma Cell Cellular Immune System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Manusow D, Weinerman BH, Hisada M, et al. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267–269.PubMedCrossRefGoogle Scholar
  2. 2.
    Hisada M, Biggar RJ, Greene MH, Fraumeni JF, Jr., Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979–1981.PubMedCrossRefGoogle Scholar
  3. 3.
    Rozman C, Montserrat E, Vinolas N. Serum immunoglobulins in B-CLL: natural history and prognostic significance. Cancer 1988; 61: 279–283.PubMedCrossRefGoogle Scholar
  4. 4.
    Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052–1057.PubMedCrossRefGoogle Scholar
  5. 5.
    Shaw R, Szwed C, Boggs D. Infection and immunity in chronic lymphocytic leukemia. Arch Intern Med 1960; 106: 467–477.CrossRefGoogle Scholar
  6. 6.
    Twomey J. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132: 562–565.PubMedCrossRefGoogle Scholar
  7. 7.
    Hartkamp A, Mulder A, Rijkers G. Antibody responses to pneumococcal and hemophilus vaccinations in patients with B-cell chronic lymphocytic leukemia. Vaccine 2001; 19: 1671–1677.PubMedCrossRefGoogle Scholar
  8. 8.
    Sampalo A, Navas G, Medina F, Segundo C, Camara C, Brieva JA. Chronic lymphocytic leukemia B-cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95–CD95L interaction. Blood 2000; 96: 3168–3174.PubMedGoogle Scholar
  9. 9.
    Kipps T, Carson D. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81: 2475–2487.PubMedGoogle Scholar
  10. 10.
    Hamblin T, Oscier D, Young B. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986; 39: 713–716.PubMedCrossRefGoogle Scholar
  11. 11.
    Kay N. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood 1981; 57: 418–420.PubMedGoogle Scholar
  12. 12.
    Kay NE, Perri RT. Immunobiology of malignant B-cells and immunoregulatory cells in B-chronic lymphocytic leukemia. Clin Lab Med 1988; 8: 163–177.PubMedGoogle Scholar
  13. 13.
    Kay N, Zarling J. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63: 305–309.PubMedGoogle Scholar
  14. 14.
    Caligaris-Cappio F, Gobbi M, Bofill M. Infrequent normal B-lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982; 155: 623–628.PubMedCrossRefGoogle Scholar
  15. 15.
    Hashimoto S, Dono M, Watai M. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+, CD5+ chronic lymphocytic leukemia B-cells. J Exp Med 1995; 181: 1507–1517.PubMedCrossRefGoogle Scholar
  16. 16.
    Panayiotidis P, Ganeshaguru K, Dforoni L, Hoffbrand A. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995; 9: 1227.PubMedGoogle Scholar
  17. 17.
    Tinhofer I, Marschitz I, Kos M, et al. Differential sensitivity of CD4+ and CD8+ T-lymphocytes to the killing efficacy of Fas (Apo-1 /CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998; 91: 4273–4281.PubMedGoogle Scholar
  18. 18.
    Conrad D, Waldschmidt T, Lee W, et al. Effect of B cell stimulatory factor-1 (interleukin 4) on Fc epsilon and Fc gamma receptor expression on murine B-lymphocytes and B cell lines. J Immunol 1987; 139: 2290–2296.PubMedGoogle Scholar
  19. 19.
    Knauf WU, Langenmayer I, Ehlers B, et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymph 1997; 27: 523–532.Google Scholar
  20. 20.
    Sarfati M. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259–4264.PubMedGoogle Scholar
  21. 21.
    Liu Y, Cairns J, Holder M, et al. Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B-cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991; 21: 1107–1114.PubMedCrossRefGoogle Scholar
  22. 22.
    Mossalayi M, Arock M, Bertho J, et al. Proliferation of early human myeloid precursors induced by interleukin1 and recombinant soluble CD23. Blood 1990; 75: 1924–1927.PubMedGoogle Scholar
  23. 23.
    Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992; 358: 505–507.PubMedCrossRefGoogle Scholar
  24. 24.
    Dorfman DM, Schultze JL, Shahsafaei A, et al. In vivo expression of B7–1 and B7–2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997; 90: 4297–4306.PubMedGoogle Scholar
  25. 25.
    Linsley P, Brady W, Grosmaire L, Aruffo A, Damle N, Ledbetter J. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173: 721–730.PubMedCrossRefGoogle Scholar
  26. 26.
    Schwartz R. Costimulation of lymphocyites: the role of CD28, CTLA-4, and B7/BB 1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065–1068.PubMedCrossRefGoogle Scholar
  27. 27.
    Eris J, Basten A, Brink R, Doherty K, Kehry M, Hodgkin P. Anergic self-reactive B-cells present self antigen and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor-mediated functions. Proc Natl Acad Sci USA 1994; 91: 4392–4396.PubMedCrossRefGoogle Scholar
  28. 28.
    Ranheim E, Kipps T. Activated T-cells induce expression of B7/BB 1 on normal or leukemic B-cells through a CD40-dependent signal. J Exp Med 1993; 177: 925–935.PubMedCrossRefGoogle Scholar
  29. 29.
    Yellin M, Sinning J, Covey L, et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B-cells or chronic lymphocytic leukemia B-cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994; 153: 666–674.PubMedGoogle Scholar
  30. 30.
    Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B-cells. J Clin Invest 1998; 101: 1133–1141.PubMedCrossRefGoogle Scholar
  31. 31.
    Ranheim E, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B-cells. Blood 1995; 85: 3556–3565.PubMedGoogle Scholar
  32. 32.
    Lotz M, Ranheim E, Kipps T. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B-cells. J Exp Med 1994; 179: 999–1004.PubMedCrossRefGoogle Scholar
  33. 33.
    Zaknoen S, Kay N. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Review 1990; 4: 165–174.CrossRefGoogle Scholar
  34. 34.
    Farace F, Orlanducci F, Dietrich P, et al. T cell repertoire in patients with B chronic lymphocytic leukemia: evidence for multiple in vivo T cell clonal expansions. J Immunol 1994; 153: 4281–4290.PubMedGoogle Scholar
  35. 35.
    Wen T, Mellstedt H, Jondal M. Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 1990; 171: 659–666.PubMedCrossRefGoogle Scholar
  36. 36.
    Rezvany M-R, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H. Oligoclonal TCRB V gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999; 94: 1063–1069.PubMedGoogle Scholar
  37. 37.
    Serrano D, Monteiro J, Allen S, et al. Clonal expansion within the CD4+ CD57+ and CD8+ CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1997; 158: 1482–1489.PubMedGoogle Scholar
  38. 38.
    Goolsby CL, Kuchnio M, Finn WG, Peterson L. Expansions of clonal and oligoclonal T-cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3+CD8+ T-cell population. Cytometry 2000; 42: 188–195.PubMedCrossRefGoogle Scholar
  39. 39.
    Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T-cells. Br J Haematol 1997; 96: 733–735.PubMedCrossRefGoogle Scholar
  40. 40.
    de Totero D, Reato G, Mauro F, et al. IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukemia. Br J Haematol 1999; 104: 589–599.PubMedCrossRefGoogle Scholar
  41. 41.
    Kay NE, Han L, Bone ND, Williams G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B-cells and blood CD8+ T-cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Hematol 2001; 112: 760–767.CrossRefGoogle Scholar
  42. 42.
    Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B-cells from death by apoptosis and upregulates Bc1–2 expression. J Exp Med 1992; 176: 1319–1326.PubMedCrossRefGoogle Scholar
  43. 43.
    Mainou-Fowler T, Craig V, Copplestone J, Hamon M, Prentice A. Effect of anti-APO1 on spontaneous apoptosis of B-cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4. Leuk Lymph 1995; 19: 301–308.CrossRefGoogle Scholar
  44. 44.
    Mainou-Fowler T, Copplestone J, Prentice A. Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells. J Clin Pathol 1995; 48: 482–487.PubMedCrossRefGoogle Scholar
  45. 45.
    Huang R, Tsuda H, Takatsuki K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells. Int J Hematol 1993; 58: 83–92.PubMedGoogle Scholar
  46. 46.
    Buschle M, Campana D, Carding S, Richard C, Hoffbrand A, Brenner M. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177: 213–218.PubMedCrossRefGoogle Scholar
  47. 47.
    Mainou-Fowler T, Craig V, Copplestone J, Hamon M, Prentice A. Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bc1–2 expression and is inhibited by IL-4. Blood 1994; 84: 2297–2304.PubMedGoogle Scholar
  48. 48.
    Fluckiger A, Durand I, Banchereau J. Interleukin 10 induces apoptotic cell death lymphocytic leukemia cells. J Exp Med 1994; 179: 91–99.PubMedCrossRefGoogle Scholar
  49. 49.
    Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990; 76: 393–400.PubMedGoogle Scholar
  50. 50.
    Mainou-Fowler T, Miller S, Proctor SJ, Dickinson AM. The levels of TNF-a, IL-4 and IL-10 production by T-cells in B-cell chronic lymphocytic leukemia (B-CLL). Leuk Res 2001; 25: 157–163.PubMedCrossRefGoogle Scholar
  51. 51.
    Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T-cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Hematol 2001; 112: 959–964.CrossRefGoogle Scholar
  52. 52.
    Kaleem Z, White G, Zutter MM. Aberrant expression of T-cell associated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2001; 115: 396–403.PubMedCrossRefGoogle Scholar
  53. 53.
    Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4+CD25+ T-cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303–1310.PubMedCrossRefGoogle Scholar
  54. 54.
    Vuillier F, Tortevoye P, Binet JL, Dighiero G. CD4, CD8 and NK subsets in B-CLL. Nouv Rev Fr Hematol 1988; 30: 331–334.PubMedGoogle Scholar
  55. 55.
    Apostolopoulos A, Symeonidis A, Zoumbos N. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia. Eur J Haematol 1990; 44: 39–44.PubMedCrossRefGoogle Scholar
  56. 56.
    Frolova E, Richards S, Jones R, et al. Immunophenotypic and DNA genotypic analysis of T-cell and NK-cell subpopulations in patients with B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Lymph 1995; 16: 307–318.CrossRefGoogle Scholar
  57. 57.
    Ziegler H, Kay NE, Zarling J. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27: 321–327.PubMedCrossRefGoogle Scholar
  58. 58.
    Alvarez de Mon M, Casas J, Laguna R, Toribio M, deLandazuri M, Durantez A. Lymphokine induction of NKlike cytotoxicity in T-cells from B-CLL. Blood 1986; 67: 228–232.Google Scholar
  59. 59.
    Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos G. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol 1996; 96: 16–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin Immunol 2001; 13: 291–302.PubMedCrossRefGoogle Scholar
  61. 61.
    Bleijs DA, Geijtenbeek TB, Figdor CG, van Kooyk Y. DC-SIGN and LFA-1: a battle for ligand. Trends Immunol 2001; 22: 457–463.PubMedCrossRefGoogle Scholar
  62. 62.
    Vuillier F, Maloum K, Thomas E, Jouanne C, Dighiero G, Scott-Algara D. Monocyte-derived dendritic cells from CLL patients display normal phenotypic and functional properties but spontaneously secrete IL-10. Blood 2001; 98: 287b.Google Scholar
  63. 63.
    Chilosi M, Pizzolo G, Caligaris-Cappio F, et al. Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia. Cancer 1985; 56: 328–332.PubMedCrossRefGoogle Scholar
  64. 64.
    Stadelmeyer E, Grube R, Chraust S, Linkesch W, Strunk D. Alteration of dendritic cell function in B-CLL. Blood 2001; 98: 287b.Google Scholar
  65. 65.
    Orsini E, Chiaretti S, Mauro F, Guarini A, Foa R. Defective dendritic cell compartment in chronic lymphocytic leukemia patients. Blood 2001; 98: 731a.Google Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Patrick B. Johnston
  • Neil E. Kay

There are no affiliations available

Personalised recommendations